U.S. Physical Therapy Reports Second Quarter 2025 Results
Reports All-time Record Patient Visits
Raises Full Year 2025 Earnings Guidance
FINANCIAL HIGHLIGHTS
-
Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles (“GAAP”) measure, was
$26.9 million $4.7 million 21.4% , from$22.1 million -
Net income attributable to USPH’s shareholders (“USPH Net Income”), a GAAP measure, was
$12.4 million $7.5 million $0.58 $0.47 -
Operating Results (1), a non-GAAP measure, was
$12.4 million $11.0 million 11.8% over the same period. On a per share basis, Operating Results was$0.81 $0.73 -
Total revenue from physical therapy operations for the 2025 Second Quarter increased
$24.8 million 17.3% , to$168.3 million -
Net rate per patient visit for the 2025 Second Quarter was
$105.33 $105.05 2.9% Medicare rate reduction which went into effect on January 1, 2025. -
Total patient visits were 1,558,756 for the 2025 Second Quarter, a
16.7% increase from the 2024 Second Quarter. Total patient visits includes 28,493 home-care visits, which the Company will break out separately each period going forward. For the six months ended June 30, 2025, the Company had 3,002,561 total patient visits, which includes 51,436 home-care visits. There were no home-care visits in the first six months of 2024. - Average daily patient visits per clinic, which does not include home-care visits, was an all-time high of 32.7 for the 2025 Second Quarter compared to 30.6 for the 2024 Second Quarter.
-
Industrial injury prevention services (“IIP”) revenue was
$29.1 million 22.6% as compared to the 2024 Second Quarter. IIP gross profit was$6.4 million $1.3 million 25.8% , from$5.1 million - The Company added six clinics and closed four clinics in the 2025 Second Quarter bringing its total owned and/or managed clinic count to 768 as of June 30, 2025, compared to 722 as of June 30, 2024.
-
On April 30, 2025, the Company announced the acquisition of an outpatient home-care physical and speech therapy practice through its
50% -owned subsidiary, MSO Metro, LLC. MSO Metro LLC. acquired80% of equity interests of the practice, with the original practice owners retaining20% of equity interests. The practice currently generates approximately$2.1 million -
On July 31, 2025, the Company acquired a
60% equity interest in a three-clinic practice with the practice owners retaining a40% equity interest. The business currently generates$5.3 million -
The Company’s Board of Directors declared a quarterly dividend of
$0.45 -
Management increased its guidance for Adjusted EBITDA for full-year 2025 to a range of
$93.0 million $97.0 million
| _______________________ | |
(1) |
These are non-GAAP Measures. See pages 13 to 15 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other non-GAAP measures to the most directly comparable GAAP measure. |
MANAGEMENT’S COMMENTS
Chris Reading, Chief Executive Officer, said, “Volumes in our physical therapy business remain at record levels while we execute our plan for cost rationalization and improved efficiencies. Our injury prevention business continues a strong growth path, both organically and through carefully added acquisitions, which have broadened our service offerings and increased our exposure to new industry verticals. As a result of our efforts and expected progress we have updated our earnings guidance for the year.”
2025 Second Quarter Versus 2024 Second Quarter
Additional supplemental tables of financial and performance metrics are presented on page 16 of this release.
Physical Therapy Operations
Three Months Ended |
Variance |
|||||||||||||
June 30, 2025 |
June 30, 2024 |
$ |
% |
|||||||||||
(In thousands, except percentages) |
||||||||||||||
Revenue related to: |
||||||||||||||
Mature Clinics (1) |
$ |
133,650 |
|
$ |
133,366 |
|
$ |
284 |
|
|
||||
Clinic additions (2) |
|
30,533 |
|
|
3,586 |
|
|
26,947 |
|
* |
(7) |
|||
Clinics sold or closed (3) |
|
- |
|
|
3,319 |
|
|
(3,319 |
) |
* |
(7) |
|||
Net Patient Revenue |
|
164,183 |
|
|
140,271 |
|
|
23,912 |
|
|
||||
Other (4) |
|
4,109 |
|
|
3,215 |
|
|
894 |
|
|
||||
Total |
|
168,292 |
|
|
143,486 |
|
|
24,806 |
|
|
||||
Operating costs (5) |
|
133,059 |
|
|
114,703 |
|
|
18,356 |
|
|
||||
Gross profit |
$ |
35,233 |
|
$ |
28,783 |
|
$ |
6,450 |
|
|
||||
Financial and operating metrics (not in thousands): |
||||||||||||||
Net rate per patient visit (1) |
$ |
105.33 |
|
$ |
105.05 |
|
$ |
0.28 |
|
|
||||
Patient visits (1) |
|
1,558,756 |
|
|
1,335,335 |
|
|
223,421 |
|
|
||||
Average daily visits per clinic (1) |
|
32.7 |
|
|
30.6 |
|
|
2.1 |
|
|
||||
Adjusted gross profit margin (5)(6) |
|
21.1 |
% |
|
20.1 |
% |
||||||||
Salaries and related costs per visit (6) |
$ |
60.08 |
|
$ |
59.66 |
|
$ |
0.42 |
|
|
||||
Operating costs per visit (6) |
$ |
83.95 |
|
$ |
84.46 |
|
$ |
(0.51 |
) |
(0.6)% |
||||
| _______________________ | |
(1) |
See Glossary of Terms - Revenue Metrics for definitions. |
(2) |
Includes six clinics added during the 2025 Second Quarter, 14 clinics added during the three months ended March 31, 2025 ("2025 First Quarter") and 96 clinics added during the year ended December 31, 2024. (Owned) |
(3) |
Includes three clinics closed during the 2025 Second Quarter, seven clinics closed in the 2025 First Quarter and 45 clinics closed during the year ended December 31, 2024. (Owned) |
(4) |
Includes revenues from management contracts. |
(5) |
Includes costs from management contracts. |
(6) |
Excludes |
(7) |
Not meaningful. |
Net revenue from physical therapy operations increased
Operating costs from physical therapy operations increased
Gross profit from physical therapy operations for the 2025 Second Quarter was
Industrial Injury Prevention Services
Three Months Ended |
Variance |
||||||||||||
June 30, 2025 |
June 30, 2024 |
$ |
% |
||||||||||
(In thousands, except percentages) |
|||||||||||||
Net revenue |
$ |
29,052 |
|
$ |
23,704 |
|
$ |
5,348 |
22.6 |
% |
|||
Operating costs |
|
22,661 |
|
|
18,625 |
|
|
4,036 |
21.7 |
% |
|||
Gross profit |
$ |
6,391 |
|
$ |
5,079 |
|
$ |
1,312 |
25.8 |
% |
|||
Gross margin |
|
22.0 |
% |
|
21.4 |
% |
|||||||
IIP revenue increased
Corporate Office and Other Expenses
Corporate office costs increased to
The Company revalued contingent consideration related to certain acquisitions and recognized a net gain (a decrease in the related liabilities) of
Operating income was
Interest expense increased by
Interest income was less than
The Company revalued a put-right liability related to the future purchase of an IIP business and recognized a net non-cash expense (an increase in the related liability) of
The provision for income taxes was
USPH Net Income and Non-GAAP Measures
Net income attributable to non-controlling interest (temporary and permanent) was
USPH Net Income was
Non-GAAP Adjusted EBITDA (1) was
| _______________________ | |
(1) |
These are Non-GAAP Measures. See pages 13 to 15 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results, and other non-GAAP measures to the most directly comparable GAAP measure. |
2025 Six Months Versus 2024 Six Months
Total net revenue for the six months ended June 30, 2025 (“2025 Six Months”) increased
Revenues from physical therapy operations increased
Revenues from IIP increased
Corporate office costs were
The Company revalued contingent consideration related to certain acquisitions and recognized a net gain (a decrease in the related liabilities) of
Operating income was
Other expenses were
The provision for income tax was
USPH Net Income was
Non-GAAP Adjusted EBITDA increased
See pages 13 to 15 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other non-GAAP measures to the most directly comparable GAAP measure.
For additional information on 2025 Six Months results, please refer to the Company’s Quarterly Report on Form 10-Q which is expected to be filed with the Securities and Exchange Commission on August 8, 2025.
BALANCE SHEET AND CASH FLOW
Total cash and cash equivalents were
RECENT ACQUISITIONS
On April 30, 2025, the Company announced the acquisition of an outpatient home-care physical and speech therapy practice through its
On July 31, 2025, the Company acquired a
The Company’s strategy is to continue acquiring multi-clinic outpatient physical therapy practices and home-care physical and speech therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships, and to continue acquiring companies that provide industrial injury prevention services.
2025 EARNINGS GUIDANCE
Management raised its Adjusted EBITDA guidance for full year 2025 to a range of
The annual earnings guidance figures will not be updated unless there is a material development that causes management to believe that Adjusted EBITDA will be significantly outside the given range.
QUARTERLY DIVIDEND
The Company’s Board of Directors declared a quarterly dividend of
SHARE REPURCHASE PROGRAM
The Company’s Board of Directors approved a share repurchase program effective August 5, 2025. The program authorizes the repurchase by the Company of up to
CONFERENCE CALL INFORMATION
FORWARD LOOKING STATEMENTS
This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
- private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply ;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants;
- certain of our acquisition agreements contain put-rights related to a future purchase of significant equity interests in our subsidiaries or in a separate company;
- the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
- our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business;
- changes as the result of government enacted national healthcare reform;
- the ability to control variable interest entities for which we do not have a direct ownership;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
- revenue and earnings expectations;
- contingent consideration provisions in certain of our acquisition agreements, the value of which may impact future financial results;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions, including but not limited to inflationary and recessionary periods;
-
actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the
U.S or the international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations; - our business depends on hiring, training, and retaining qualified employees;
- availability and cost of qualified physical therapists;
- competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line;
- our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses;
- impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
- maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
- a security breach of our or our third party vendors’ information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
- maintaining clients for which we perform management, industrial injury prevention related services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 3, 3025 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.
GLOSSARY OF TERMS – REVENUE METRICS
Mature clinics are clinics (physical clinic locations and home-care business units) opened or acquired prior to January 1, 2024, and are still operating as of the balance sheet date.
Net rate per patient visit is net patient revenue related to our physical therapy operations divided by total number of patient visits (defined below) during the periods presented.
Patient visits is the number of unique patient visits during the periods presented for both physical clinic locations and home-care.
Average daily visits per clinic per day is patient visits (excluding home-care visits) divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of clinics in operation during the periods presented.
ABOUT U.S. PHYSICAL THERAPY, INC.
Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 774 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES |
|||||||||||||||
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME |
|||||||||||||||
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) |
|||||||||||||||
Three Months Ended |
|
Six Months Ended |
|||||||||||||
June 30, 2025 |
|
June 30, 2024 |
|
June 30, 2025 |
|
June 30, 2024 |
|||||||||
|
|
|
|
|
|
||||||||||
Net patient revenue |
$ |
164,183 |
|
$ |
140,271 |
|
$ |
316,730 |
|
$ |
271,346 |
|
|||
Other revenue |
|
33,161 |
|
|
26,919 |
|
|
64,402 |
|
|
51,519 |
|
|||
Net revenue |
|
197,344 |
|
|
167,190 |
|
|
381,132 |
|
|
322,865 |
|
|||
Operating cost: |
|||||||||||||||
Salaries and related costs |
|
113,788 |
|
|
96,334 |
|
|
225,037 |
|
|
190,065 |
|
|||
Rent, supplies, contract labor and other |
|
34,127 |
|
|
30,335 |
|
|
67,971 |
|
|
58,319 |
|
|||
Depreciation and amortization |
|
5,741 |
|
|
4,299 |
|
|
11,281 |
|
|
8,197 |
|
|||
Provision for credit losses |
|
1,995 |
|
|
1,717 |
|
|
3,843 |
|
|
3,344 |
|
|||
Clinic closure costs - lease and other |
|
69 |
|
|
643 |
|
|
311 |
|
|
677 |
|
|||
Total operating cost |
|
155,720 |
|
|
133,328 |
|
|
308,443 |
|
|
260,602 |
|
|||
Gross profit |
|
41,624 |
|
|
33,862 |
|
|
72,689 |
|
|
62,263 |
|
|||
Corporate office costs |
|
17,476 |
|
|
14,249 |
|
|
33,721 |
|
|
28,334 |
|
|||
(Gain) loss on change in fair value of contingent earn-out consideration |
|
(790 |
) |
|
4,046 |
|
|
(5,612 |
) |
|
3,434 |
|
|||
Operating income |
|
24,938 |
|
|
15,567 |
|
|
44,580 |
|
|
30,495 |
|
|||
Other income (expense): |
|||||||||||||||
Interest expense, debt and other |
|
(2,422 |
) |
|
(1,980 |
) |
|
(4,701 |
) |
|
(3,948 |
) |
|||
Interest income from investments |
|
28 |
|
|
1,074 |
|
|
52 |
|
|
2,617 |
|
|||
Change in revaluation of put-right liability |
|
(339 |
) |
|
(223 |
) |
|
(743 |
) |
|
(303 |
) |
|||
Equity in earnings of unconsolidated affiliate |
|
401 |
|
|
248 |
|
|
794 |
|
|
519 |
|
|||
Loss on sale of a partnership |
|
- |
|
|
- |
|
|
(123 |
) |
|
- |
|
|||
Other |
|
47 |
|
|
109 |
|
|
122 |
|
|
171 |
|
|||
Total other expense |
|
(2,285 |
) |
|
(772 |
) |
|
(4,599 |
) |
|
(944 |
) |
|||
Income before taxes |
|
22,653 |
|
|
14,795 |
|
|
39,981 |
|
|
29,551 |
|
|||
Provision for income taxes |
|
4,933 |
|
|
3,083 |
|
|
8,793 |
|
|
6,222 |
|
|||
Net income |
|
17,720 |
|
|
11,712 |
|
|
31,188 |
|
|
23,329 |
|
|||
Less: Net income attributable to non-controlling interest: |
|||||||||||||||
Redeemable non-controlling interest - temporary equity |
|
(3,914 |
) |
|
(3,314 |
) |
|
(5,926 |
) |
|
(5,541 |
) |
|||
Non-controlling interest - permanent equity |
|
(1,413 |
) |
|
(892 |
) |
|
(2,970 |
) |
|
(2,236 |
) |
|||
|
(5,327 |
) |
|
(4,206 |
) |
|
(8,896 |
) |
|
(7,777 |
) |
||||
Net income attributable to USPH shareholders |
$ |
12,393 |
|
$ |
7,506 |
|
$ |
22,292 |
|
$ |
15,552 |
|
|||
Basic and diluted earnings per share attributable to USPH shareholders (1) |
$ |
0.58 |
|
$ |
0.47 |
|
$ |
1.38 |
|
$ |
0.93 |
|
|||
Shares used in computation - basic and diluted |
|
15,197 |
|
|
15,072 |
|
|
15,165 |
|
|
15,044 |
|
|||
Dividends declared per common share |
$ |
0.45 |
|
$ |
0.44 |
|
$ |
0.90 |
|
$ |
0.88 |
|
|||
(1) See page 14 of this press release for the calculation of basic and diluted earnings per share. |
|||||||||||||||
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES |
|||||||||||||||
UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME |
|||||||||||||||
(IN THOUSANDS) |
|||||||||||||||
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
June 30, 2025 |
|
June 30, 2024 |
|
June 30, 2025 |
|
June 30, 2024 |
||||||||
|
|||||||||||||||
Net income |
$ |
17,720 |
|
$ |
11,712 |
|
$ |
31,188 |
|
$ |
23,329 |
|
|||
Other comprehensive (loss) gain: |
|||||||||||||||
Unrealized (loss) gain on cash flow hedge |
|
(798 |
) |
|
(31 |
) |
|
(2,129 |
) |
|
1,750 |
|
|||
Tax effect at statutory rate (federal and state) |
|
204 |
|
|
8 |
|
|
544 |
|
|
(447 |
) |
|||
Comprehensive income |
$ |
17,126 |
|
$ |
11,689 |
|
$ |
29,603 |
|
$ |
24,632 |
|
|||
|
|||||||||||||||
Comprehensive income attributable to non-controlling interest |
|
(5,327 |
) |
|
(4,206 |
) |
|
(8,896 |
) |
|
(7,777 |
) |
|||
Comprehensive income attributable to USPH shareholders |
$ |
11,799 |
|
$ |
7,483 |
|
$ |
20,707 |
|
$ |
16,855 |
|
|||
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES |
|||||||
CONSOLIDATED BALANCE SHEET |
|||||||
(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS) |
|||||||
June 30, 2025 |
|
December 31, 2024 |
|||||
ASSETS |
(unaudited) |
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
34,086 |
|
$ |
41,362 |
|
|
Patient accounts receivable, less provision for credit losses of |
|
65,956 |
|
|
59,040 |
|
|
Accounts receivable - other |
|
27,429 |
|
|
26,626 |
|
|
Other current assets |
|
13,061 |
|
|
10,555 |
|
|
Total current assets |
|
140,532 |
|
|
137,583 |
|
|
Fixed assets: |
|||||||
Furniture and equipment |
|
66,756 |
|
|
68,128 |
|
|
Leasehold improvements |
|
55,218 |
|
|
51,105 |
|
|
Fixed assets, gross |
|
121,974 |
|
|
119,233 |
|
|
Less accumulated depreciation and amortization |
|
(89,853 |
) |
|
(87,093 |
) |
|
Fixed assets, net |
|
32,121 |
|
|
32,140 |
|
|
Operating lease right-of-use assets |
|
137,248 |
|
|
133,936 |
|
|
Investment in unconsolidated affiliate |
|
12,320 |
|
|
12,190 |
|
|
Goodwill |
|
677,595 |
|
|
667,152 |
|
|
Other identifiable intangible assets, net |
|
175,627 |
|
|
179,311 |
|
|
Other assets |
|
4,157 |
|
|
5,155 |
|
|
Total assets |
$ |
1,179,600 |
|
$ |
1,167,467 |
|
|
|
|||||||
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTEREST |
|||||||
Current liabilities: |
|||||||
Accounts payable - trade |
$ |
4,200 |
|
$ |
5,936 |
|
|
Accrued expenses |
|
65,436 |
|
|
59,513 |
|
|
Current portion of operating lease liabilities |
|
41,038 |
|
|
39,835 |
|
|
Current portion of term loan and notes payable |
|
8,168 |
|
|
10,999 |
|
|
Total current liabilities |
|
118,842 |
|
|
116,283 |
|
|
Notes payable, net of current portion |
|
321 |
|
|
903 |
|
|
Revolving facility |
|
24,500 |
|
|
11,000 |
|
|
Term loan, net of current portion and deferred financing costs |
|
127,093 |
|
|
130,627 |
|
|
Deferred taxes |
|
34,402 |
|
|
29,465 |
|
|
Operating lease liabilities, net of current portion |
|
104,279 |
|
|
101,868 |
|
|
Other long-term liabilities |
|
4,571 |
|
|
18,275 |
|
|
Total liabilities |
|
414,008 |
|
|
408,421 |
|
|
|
|||||||
Redeemable non-controlling interest - temporary equity |
|
263,298 |
|
|
269,025 |
|
|
|
|||||||
Commitments and Contingencies |
|||||||
|
|||||||
U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: |
|||||||
Preferred stock, |
|
- |
|
|
- |
|
|
Common stock, |
|
172 |
|
|
172 |
|
|
Additional paid-in capital |
|
294,636 |
|
|
|
290,321 |
|
Accumulated other comprehensive gain |
|
1,214 |
|
|
2,799 |
|
|
Retained earnings |
|
236,356 |
|
|
227,265 |
|
|
Treasury stock at cost, 2,214,737 shares |
|
(31,628 |
) |
|
(31,628 |
) |
|
Total USPH shareholders’ equity |
|
500,750 |
|
|
488,929 |
|
|
Non-controlling interest - permanent equity |
|
1,544 |
|
|
1,092 |
|
|
Total USPH shareholders' equity and non-controlling interest - permanent equity |
|
502,294 |
|
|
490,021 |
|
|
Total liabilities, redeemable non-controlling interest, USPH shareholders' equity and non-controlling interest - permanent equity |
$ |
1,179,600 |
|
$ |
1,167,467 |
|
|
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES |
|||||||
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
(IN THOUSANDS) |
|||||||
|
Six Months Ended |
||||||
|
June 30, 2025 |
|
June 30, 2024 |
||||
OPERATING ACTIVITIES |
|||||||
Net income including non-controlling interest |
$ |
31,188 |
|
$ |
23,329 |
|
|
Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities: |
|||||||
Depreciation and amortization |
|
11,924 |
|
|
8,609 |
|
|
Provision for credit losses |
|
3,843 |
|
|
3,344 |
|
|
Equity-based awards compensation expense |
|
3,888 |
|
|
3,916 |
|
|
Amortization of debt issue costs |
|
210 |
|
|
210 |
|
|
Change in deferred income taxes |
|
7,279 |
|
|
770 |
|
|
Change in revaluation of put-right liability |
|
743 |
|
|
303 |
|
|
Change in fair value of contingent earn-out consideration |
|
(5,612 |
) |
|
3,434 |
|
|
Equity of earnings in unconsolidated affiliate |
|
(794 |
) |
|
(519 |
) |
|
Loss on sale of fixed assets |
|
438 |
|
|
51 |
|
|
Loss on sale of a partnership |
|
123 |
|
|
- |
|
|
Changes in operating assets and liabilities: |
|||||||
Patient accounts receivable, net |
|
(10,232 |
) |
|
(5,110 |
) |
|
Accounts receivable - other |
|
355 |
|
|
(2,351 |
) |
|
Other current and long term assets |
|
(4,426 |
) |
|
(1,642 |
) |
|
Accounts payable and accrued expenses |
|
(7,914 |
) |
|
(1,481 |
) |
|
Other long-term liabilities |
|
(827 |
) |
|
548 |
|
|
Net cash provided by operating activities |
|
30,186 |
|
|
33,411 |
|
|
INVESTING ACTIVITIES |
|||||||
Purchase of fixed assets |
|
(5,830 |
) |
|
(4,174 |
) |
|
Purchase of majority interest in businesses, net of cash acquired |
|
(6,890 |
) |
|
(38,695 |
) |
|
Purchase of redeemable non-controlling interest, temporary equity |
|
(8,427 |
) |
|
(6,230 |
) |
|
Purchase of non-controlling interest, permanent equity |
|
(149 |
) |
|
(527 |
) |
|
Proceeds from the sale of non-controlling interest, permanent equity |
|
9 |
|
|
26 |
|
|
Proceeds from the sale of partnership interest - redeemable non-controlling interest, temporary equity |
|
15 |
|
|
69 |
|
|
Repayment of notes receivable related to redeemable non-controlling interest |
|
346 |
|
|
375 |
|
|
Proceeds from the sale of partnership |
|
700 |
|
|
- |
|
|
Distributions from unconsolidated affiliate |
|
664 |
|
|
532 |
|
|
Other |
|
228 |
|
|
(131 |
) |
|
Net cash (used in) investing activities |
|
(19,334 |
) |
|
(48,755 |
) |
|
FINANCING ACTIVITIES |
|||||||
Proceeds from revolving facility |
|
73,500 |
|
|
- |
|
|
Payments on revolving facility |
|
(60,000 |
) |
|
- |
|
|
Distributions to non-controlling interest, permanent and temporary equity |
|
(10,697 |
) |
|
(8,318 |
) |
|
Cash dividends paid to shareholders |
|
(13,678 |
) |
|
(13,264 |
) |
|
Payments on term loan |
|
(5,625 |
) |
|
(1,875 |
) |
|
Principal payments on notes payable |
|
(1,628 |
) |
|
(1,113 |
) |
|
Net cash (used in) financing activities |
|
(18,128 |
) |
|
(24,570 |
) |
|
Net (decrease) in cash and cash equivalents |
|
(7,276 |
) |
|
(39,914 |
) |
|
Cash and cash equivalents - beginning of period |
|
41,362 |
|
|
152,825 |
|
|
Cash and cash equivalents - end of period |
$ |
34,086 |
|
$ |
112,911 |
|
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |
|||||||
Cash paid during the period for: |
|||||||
Income taxes |
$ |
9,833 |
|
$ |
4,932 |
|
|
Interest paid |
|
4,683 |
|
|
3,708 |
|
|
Non-cash investing and financing transactions during the period: |
|||||||
Purchase of businesses - seller financing portion |
|
- |
|
|
955 |
|
|
Fair market value of initial contingent consideration related to purchase of businesses |
|
3,059 |
|
|
2,800 |
|
|
Offset of notes receivable associated with purchase of redeemable non-controlling interest |
|
254 |
|
|
75 |
|
|
Notes payable related to purchase of non-controlling interest, temporary equity |
|
- |
|
|
22 |
|
|
Notes payable related to purchase of redeemable non-controlling interest, temporary equity |
|
89 |
|
|
- |
|
|
Notes receivable related to sale of redeemable non-controlling interest, temporary equity |
|
660 |
|
|
402 |
|
|
Notes receivable related to the sale of non-controlling interest, permanent equity |
|
29 |
|
243 |
|||
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
ADJUSTED EBITDA AND OPERATING RESULTS
The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA and Operating Results. The tables also provide a reconciliation of additional non-GAAP measures to the most comparable GAAP measure. Management believes providing Adjusted EBITDA and Operating Results to investors is useful for comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures. Management uses Adjusted EBITDA and Operating Results, which eliminate certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period.
Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, changes in revaluation of put-right liability, equity-based awards compensation expense, clinic closure costs, business acquisition related costs, costs related to a one-time financial and human resources systems upgrade, loss on sale of a partnership and other income and related portions for non-controlling interests.
Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less, changes in revaluation of a put-right liability, clinic closure costs, loss on sale of a partnership, changes in fair value of contingent earn-out consideration, business acquisition related costs, costs related to a one-time financial and human resources systems upgrade and any allocations to non-controlling interests, all net of taxes. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.
Adjusted EBITDA and Operating Results are not measures of financial performance under GAAP. Adjusted EBITDA, Operating Results and other non-GAAP measures should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES |
|||||||||||||||
ADJUSTED EBITDA, OPERATING RESULTS AND EARNINGS PER SHARE |
|||||||||||||||
(IN THOUSANDS, EXCEPT PER SHARE DATA) |
|||||||||||||||
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
June 30, 2025 |
|
June 30, 2024 |
|
June 30, 2025 |
|
June 30, 2024 |
||||||||
(In thousands, except per share data) |
|||||||||||||||
Adjusted EBITDA (a non-GAAP measure) |
|
|
|
|
|
|
|||||||||
Net income attributable to USPH shareholders |
$ |
12,393 |
|
$ |
7,506 |
|
$ |
22,292 |
|
$ |
15,552 |
|
|||
Adjustments: |
|||||||||||||||
Provision for income taxes |
|
4,933 |
|
|
3,083 |
|
|
8,793 |
|
|
6,222 |
|
|||
Depreciation and amortization |
|
6,057 |
|
|
4,514 |
|
|
11,924 |
|
|
8,609 |
|
|||
Interest expense, debt and other, net |
|
2,422 |
|
|
1,980 |
|
|
4,701 |
|
|
3,948 |
|
|||
Equity-based awards compensation expense |
|
2,117 |
|
|
1,919 |
|
|
3,888 |
|
|
3,916 |
|
|||
Interest income from investments |
|
(28 |
) |
|
(1,074 |
) |
|
(52 |
) |
|
(2,617 |
) |
|||
Change in revaluation of put-right liability |
|
339 |
|
|
223 |
|
|
743 |
|
|
303 |
|
|||
(Gain) loss on change in fair value of contingent earn-out consideration |
|
(790 |
) |
|
4,046 |
|
|
(5,612 |
) |
|
3,434 |
|
|||
Clinic Closure costs (1) |
|
69 |
|
|
551 |
|
|
311 |
|
|
677 |
|
|||
Business acquisition related costs (2) |
|
320 |
|
|
- |
|
|
800 |
|
|
- |
|
|||
ERP implementation costs (3) |
|
159 |
|
|
- |
|
|
221 |
|
|
- |
|
|||
Loss on sale of a partnership |
|
- |
|
|
- |
|
|
123 |
|
|
- |
|
|||
Other income |
|
(47 |
) |
|
(109 |
) |
|
(122 |
) |
|
(171 |
) |
|||
Allocation to non-controlling interests |
|
(1,081 |
) |
|
(515 |
) |
|
(1,608 |
) |
|
(978 |
) |
|||
$ |
26,863 |
|
$ |
22,124 |
|
$ |
46,402 |
|
$ |
38,895 |
|
||||
Operating Results (a non-GAAP measure) |
|||||||||||||||
Net income attributable to USPH shareholders |
$ |
12,393 |
|
$ |
7,506 |
|
$ |
22,292 |
|
$ |
15,552 |
|
|||
Adjustments: |
|||||||||||||||
Gain (loss) on change in fair value of contingent earn-out consideration |
|
(790 |
) |
|
4,046 |
|
|
(5,612 |
) |
|
3,434 |
|
|||
Change in revaluation of put-right liability |
|
339 |
|
|
223 |
|
|
743 |
|
|
303 |
|
|||
Clinic closure costs (1) |
|
69 |
|
|
551 |
|
|
311 |
|
|
677 |
|
|||
Business acquisition related costs (2) |
|
320 |
|
|
- |
|
|
800 |
|
|
- |
|
|||
ERP implementation costs (3) |
|
159 |
|
|
- |
|
|
221 |
|
|
- |
|
|||
Loss on sale of a partnership |
|
- |
|
|
- |
|
|
123 |
|
|
- |
|
|||
Allocation to non-controlling interests |
|
(156 |
) |
|
(68 |
) |
|
(118 |
) |
|
(84 |
) |
|||
Tax effect at statutory rate (federal and state) |
|
16 |
|
|
(1,214 |
) |
|
903 |
|
|
(1,106 |
) |
|||
$ |
12,350 |
|
$ |
11,044 |
|
$ |
19,663 |
|
$ |
18,776 |
|
||||
Operating Results per share (a non-GAAP measure) |
$ |
0.81 |
|
$ |
0.73 |
|
$ |
1.30 |
|
$ |
1.25 |
|
|||
Earnings per share |
|||||||||||||||
Computation of earnings per share - USPH shareholders: |
|||||||||||||||
Net income attributable to USPH shareholders |
$ |
12,393 |
|
$ |
7,506 |
|
$ |
22,292 |
|
$ |
15,552 |
|
|||
Charges to retained earnings: |
|||||||||||||||
Revaluation of redeemable non-controlling interest |
|
(4,806 |
) |
|
(622 |
) |
|
(1,903 |
) |
|
(2,061 |
) |
|||
Tax effect at statutory rate (federal and state) |
|
1,228 |
|
|
159 |
|
|
486 |
|
|
527 |
|
|||
$ |
8,815 |
|
$ |
7,043 |
|
$ |
20,875 |
|
$ |
14,018 |
|
||||
Earnings per share (basic and diluted) |
$ |
0.58 |
|
$ |
0.47 |
|
$ |
1.38 |
|
$ |
0.93 |
|
|||
Shares used in computation - basic and diluted |
|
15,197 |
|
|
15,072 |
|
|
15,165 |
|
|
15,044 |
|
|||
| _______________________ | |
(1) |
Costs associated with the closure of three clinics in the 2025 Second Quarter, 10 clinics during the 2025 Six Months, five clinics in the 2024 Second Quarter and 11 clinics in the 2024 Six Months. |
(2) |
Primarily consists of retention bonuses and legal and consulting expenses related to the acquisitions of equity interests in certain partnerships. |
(3) |
Consists of costs related to a one-time financial and human resources systems upgrade. |
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP MEASURES TO THE MOST COMPARABLE GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE DATA AND PERCENTAGES)
The tables below reconcile other non-GAAP measures to the most directly comparable GAAP measures for the 2025 Second Quarter and the 2025 Six Months. No commensurate adjustments were made in the comparable prior year period.
Three Months Ended |
Six Months Ended |
||||||||||||||||||||||
June 30, 2025 |
June 30, 2025 |
||||||||||||||||||||||
As Reported
|
Adjustments (1) |
As Adjusted
|
As Reported
|
Adjustments (1) |
As Adjusted
|
||||||||||||||||||
(in thousands, except percentages) |
(in thousands, except percentages) |
||||||||||||||||||||||
Segment information - Physical Therapy Operations |
|||||||||||||||||||||||
Salaries and related costs (2) |
$ |
93,877 |
|
$ |
(229 |
) |
$ |
93,648 |
|
$ |
185,676 |
|
$ |
(294 |
) |
$ |
185,382 |
|
|||||
Operating costs (2) |
$ |
131,093 |
|
$ |
(229 |
) |
$ |
130,864 |
|
$ |
260,064 |
|
$ |
(294 |
) |
$ |
259,770 |
|
|||||
Gross profit |
$ |
35,233 |
|
$ |
229 |
|
$ |
35,462 |
|
$ |
60,701 |
|
$ |
294 |
|
$ |
60,995 |
|
|||||
Gross margin |
|
20.9 |
% |
* |
|
21.1 |
% |
|
18.7 |
% |
* |
|
18.8 |
% |
|||||||||
Number of visits |
|
1,558,756 |
|
|
1,558,756 |
|
|
3,002,561 |
|
|
3,002,561 |
|
|||||||||||
Salaries and related costs per visit |
$ |
60.23 |
|
$ |
(0.15 |
) |
$ |
60.08 |
|
$ |
61.84 |
|
$ |
(0.10 |
) |
$ |
61.74 |
|
|||||
Operating costs per visit |
$ |
84.10 |
|
$ |
(0.15 |
) |
$ |
83.95 |
|
$ |
86.62 |
|
$ |
(0.10 |
) |
$ |
86.52 |
|
|||||
| _______________________ | |
(1) |
Certain incentive costs related to the Metro acquisition. We believe that presenting this information will allow investors to evaluate the performance of the Company's business more objectively. |
(2) |
Excludes costs related to management contracts. |
| * Not meaningful | |
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES |
|||||||||||||||||
SUPPLEMENTAL FINANCIAL AND PERFORMANCE METRICS |
|||||||||||||||||
Revenue Metrics |
|||||||||||||||||
Number of Clinics (2) |
|
Net Rate Per Patient Visit (1) |
|
Patient Visits (1) |
|
Average Visits Per Clinic Per Day(3) |
|||||||||||
2025 |
|
2024 |
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|||
First quarter |
729 |
679 |
$ |
105.66 |
$ |
103.37 |
1,443,805 |
1,268,002 |
31.2 |
29.5 |
|||||||
Second quarter |
732 |
681 |
$ |
105.33 |
$ |
105.05 |
1,558,756 |
1,335,335 |
32.7 |
30.6 |
|||||||
Third quarter |
|
661 |
|
$ |
105.65 |
|
1,317,051 |
|
30.1 |
||||||||
Fourth quarter |
|
722 |
|
$ |
104.73 |
|
1,432,801 |
|
31.6 |
||||||||
Year-to-date |
722 |
|
$ |
104.71 |
3,002,561 |
5,353,189 |
|
30.4 |
|||||||||
| _______________________ | |
(1) |
See definition of the metrics above in the Glossary of Terms – Revenue Metrics section on page 7. |
(2) |
The Company also manages clinics owned by third parties through management contracts. In addition to the clinic count shown above (excluding the home-care business unit count), as of June 30, 2025, the Company managed 36 clinics bringing the total owned/managed clinics to 768. In comparison, as of June 30, 2024, the Company managed 41 clinics bringing the total owned/managed clinics to 722. |
(3) |
Excludes home-care visits. |
Clinic Count Roll Forward (1) |
|||||||||||||||||||
2025 |
|
|
2024 |
||||||||||||||||
Owned |
|
Managed |
|
Total |
|
|
Owned |
|
Managed |
|
Total |
||||||||
Number of clinics, beginning of period |
722 |
|
39 |
|
761 |
|
671 |
|
43 |
|
714 |
|
|||||||
Q1 additions |
14 |
|
- |
|
14 |
|
14 |
|
- |
|
14 |
|
|||||||
Q1 closed or sold |
(7 |
) |
(2 |
) |
(9 |
) |
(6 |
) |
(2 |
) |
(8 |
) |
|||||||
Number of clinics, end of period |
729 |
|
37 |
|
766 |
|
679 |
|
41 |
|
720 |
|
|||||||
Q2 additions |
6 |
|
- |
|
6 |
|
7 |
|
- |
|
7 |
|
|||||||
Q2 closed or sold |
(3 |
) |
(1 |
) |
(4 |
) |
(5 |
) |
- |
|
(5 |
) |
|||||||
Number of clinics, end of period |
732 |
|
36 |
|
768 |
|
681 |
|
41 |
|
722 |
|
|||||||
Q3 additions |
12 |
|
- |
|
12 |
|
|||||||||||||
Q3 closed or sold |
(32 |
) |
(2 |
) |
(34 |
) |
|||||||||||||
Number of clinics, end of period |
661 |
|
39 |
|
700 |
|
|||||||||||||
Q4 additions |
63 |
|
- |
|
63 |
|
|||||||||||||
Q4 closed or sold |
(2 |
) |
- |
|
(2 |
) |
|||||||||||||
Number of clinics, end of period |
722 |
|
39 |
|
761 |
|
|||||||||||||
Year-to-date total additions |
20 |
|
- |
|
20 |
|
96 |
|
- |
|
96 |
|
|||||||
Year-to-date total closed or sold |
(10 |
) |
(3 |
) |
(13 |
) |
(45 |
) |
(4 |
) |
(49 |
) |
|||||||
| _______________________ | |||||||||||||||||||
(1) Excludes the home-care business. |
|||||||||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806559477/en/
U.S. Physical Therapy, Inc.
Carey Hendrickson, Chief Financial Officer
email: chendrickson@usph.com
Chris Reading, Chief Executive Officer
(713) 297-7000
Three Part Advisors
Joe Noyons
(817) 778-8424
Source: U.S. Physical Therapy, Inc.
